Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Debt to Equity (2016 - 2025)

BioCorRx's Debt to Equity history spans 11 years, with the latest figure at -$0.01 for Q3 2025.

  • For Q3 2025, Debt to Equity rose 94.89% year-over-year to -$0.01; the TTM value through Sep 2025 reached -$0.01, up 94.89%, while the annual FY2024 figure was -$0.01, 105.73% down from the prior year.
  • Debt to Equity for Q3 2025 was -$0.01 at BioCorRx, up from -$0.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.1 in Q4 2023 and bottomed at -$0.72 in Q1 2021.
  • The 5-year median for Debt to Equity is -$0.09 (2024), against an average of -$0.23.
  • The largest YoY upside for Debt to Equity was 99.2% in 2021 against a maximum downside of 441.65% in 2021.
  • A 5-year view of Debt to Equity shows it stood at -$0.0 in 2021, then tumbled by 9063.64% to -$0.42 in 2022, then surged by 124.15% to $0.1 in 2023, then crashed by 105.73% to -$0.01 in 2024, then grew by 9.96% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Debt to Equity are -$0.01 (Q3 2025), -$0.01 (Q4 2024), and -$0.1 (Q3 2024).